Clinical Trial Update: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on pixatimod (PG545) plus nivolumab in PD-1 relapsed/refractory metastatic melanoma and non-small cell lung cancer, and on nivolum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Pixatimod (pixatimod)
• nivolumab (nivolumab)

Snippet

Sponsor: Diwakar Davar | Conditions: NSCLC, Metastatic Colorectal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-07